Can ADCs broaden the treatment landscape of metastatic ER+/HER2- breast cancer resistant to CDK4/6 inhibition?

Karen Van Baelen; Christine Desmedt; Hans Wildiers; Patrick Neven

doi:10.21037/atm-23-41

Can ADCs broaden the treatment landscape of metastatic ER+/HER2- breast cancer resistant to CDK4/6 inhibition?

Ann Transl Med. 2023 Mar 31;11(6):269. doi: 10.21037/atm-23-41. Epub 2023 Feb 28.

Authors

Karen Van Baelen¹, Christine Desmedt¹, Hans Wildiers², Patrick Neven³

Affiliations

¹ Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Belgium.
² Department of General Medical Oncology and Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium.
³ Department of Gynecological Oncology and Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium.

No abstract available

Keywords: Antibody-drug conjugates (ADCs); CDK4/6 inhibition resistance; metastatic breast cancer; oestrogen receptor positive/human epidermal growth factor receptor 2 negative breast cancer (ER+/HER2− breast cancer).

Publication types

Editorial
Comment